Background. MRSA-USA300 is a community-associated clone that has spread worldwide, becoming the most successful clone in the USA. Since 2005, the MRSA-USA300 Latin-American Variant (USA300-LV) has disseminated in community and hospitals in Northern South America. Phylogenetic analysis revealed that USA300-LV is not derived from the USA300 (NA-USA300) but rather, the two clones diverged from a common ancestor. During their evolution, NA-USA300 strains incorporated the ACME element and USA300-LV acquired a copper and mercury resistance mobile element designated COMER. Interestingly, contamination by heavy metals in South American has been recently highlighted and could be driving the selection of resistant genetic lineages. We investigated the frequency of merA, merB, and copB in genomes of clinical isolates of S. aureus from Latin America (LA).
Methods. The presence of merA/merB and copB encoding mercury and copper resistance, respectively, were investigated in 515 S. aureus sequenced genomes recovered from bacteremic patients in hospitals from nine Latin American hospitals trough BLAST searches.
Results. The prevalence of merAB in S. aureus was 35% (181 out of 515 genomes). Interestingly, among 181 merAB-positive S. aureus, 174 were MRSA (96%). Moreover, 71%, 60%, 59%, and 51% of MRSA genomes from Peru, Ecuador, Colombia, and Venezuela, respectively, harbored mercury resistance genes. Similarly, 65%, 60%, and 22% of MRSA genomes from Ecuador, Colombia, and Venezuela, contained the copB gene. Among 174 MRSA harboring merAB, ST8 and ST5 were the most predominant lineages in (43% and 45% of genomes, respectively). In contrast, among 95 MRSA carrying copB, ST8 was the most frequent lineage (96% of isolates). MRSA from countries with high prevalence of mercury genes showed association with ST5 and ST8. 88% of Colombian and 87% of Ecuadorian MRSA harboring merAB belonged to ST8 lineage, whereas ST5 was predominant in 88% of Peruvian MRSA. In Venezuela, ST5 and ST8 were found in 44% and 33%, respectively, of MRSA positive for merAB.
Conclusion. There is a paucity of data on VRSA in developing nations. We seek to define the prevalence and resistance profile of SA in the Dominican Republic (DR).
Methods. This is a retrospective review of resistance patterns of SA isolates from a clinical laboratory in the DR (Amadita Laboratories). Amadita provides services nationwide. Data collected from 2016 to 2017 included SA phenotypic sensitivity patterns and geographic location and income level. VISA and VRSA were defined as having minimum inhibitory (MIC) concentrations between 4 and 8 and MIC >16.
Results. Of 5,372 SA samples, 2,735 (51%) were MRSA, 21 were VISA and 39 were VRSA. VRSA samples were more commonly from Santo Domingo (SD) (Figure 1 ). Communities in SD with mixed and low incomes had greater burden of VRSA (Figure 2) . Antimicrobial susceptibilities are shown in Table 1 . 
Conclusion.
In this nationwide sample, we found an alarming number of VISA and VRSA. Most cases were in metropolitan SD, with lower income communities carrying a higher case burden. Linezolid and TMP-SMX retain activity against VISA and VRSA in the DR. The rise of vancomycin resistance in developing countries and the disproportionate burden on communities of low income is concerning and requires further study. Infection control measures and antimicrobial stewardship interventions may help prevent further spread of resistant strains.
Disclosures. All authors: No reported disclosures. Background. β-Lactams remain the gold standard for treatment of MSSA bacteremia due to superior outcomes compared with vancomycin. Approximately nine in 10 patients receiving penicillin skin testing (PST) will be de-labeled of a penicillin allergy and able to receive a β-lactam antibiotic. The study aims to evaluate the cost-effectiveness of penicillin allergy confirmation during acute care admission for methicillin-sensitive staphylococcus aureus (MSSA) bacteremia through a PST service.
Cost-Effectiveness of Penicillin Skin Allergy Testing in Methicillin-Sensitive
Methods. A decision tree analysis was used to compare a PST intervention in patients with a registeredpenicillin allergy during an inpatient admission for MSSA bacteremia vs. usual care (No PST). The model was created from the health sector perspective with a 1-year time horizon. Patients with a penicillin allergy label were expected to receive vancomycin while patients with no penicillin allergy were expected to receive cefazolin. Potential inpatient, outpatient, and adverse reaction costs were considered in all arms of the model. The effects were measured in quality adjusted life years (QALY) and were calculated for patients who were cured, hospitalized, experienced severe adverse events, or died from MSSA infection.
Results. Patients who received PST services had a mean yearly cost of $12,802, mean quality adjusted life years (QALY) of 0.70, and mean cost/QALY of $18,311. The comparator group not receiving PST services had a mean yearly cost of $12,264, mean quality adjusted life years (QALY) of 0.64, and mean cost/QALY of $19,192. The model produced a final base case ICERof $8,966/QALY for receiving a PST during a hospital admission for the treatment of methicillin-sensitive staphylococcus aureus (MSSA) bacteremia.
Conclusion. Penicillin allergy confirmation through PST services was cost-effective for patients with a reported penicillin allergy admitted for MSSA bacteremia. Additional research to determine potential benefits of PST services beyond one year could further improve the cost-effectiveness of this intervention. Background. In the NICU, MSSA is a more prevalent pathogen than MRSA, but optimal infection prevention and control strategies for MSSA are not yet well understood. There are likely multiple routes of MSSA acquisition given its role as normal flora and its detection in the anovaginal tract of pregnant women. We describe the molecular epidemiology of MSSA in our NICU during a yearlong surveillance effort.
Methods. Included infants were hospitalized in a university-affiliated level III-IV NICU from January to December 2017 (1032 admissions) and had positive clinical and/or surveillance cultures for MSSA. Infants admitted at ≥7 days of age were screened for MSSA colonization by culturing the anterior nares and three skin sites. All infants in the NICU were screened twice monthly. Spa typing was performed to genetically characterize isolates.
Results. During the study period, MSSA was identified in 187 infants (18 at admission, 145 by twice monthly surveillance, and 24 from clinical cultures). In all, 269 MSSA isolates (245 surveillance and 24 clinical isolates) from 166 infants were spa typed. Sixty-two MSSA spa types were identified; 31 (50%) were each detected in only one infant. The incidence of the nine most common spa types is shown ( Figure 1) ; t279 (13%), t002 (8%), and t1451 (6%) had the highest incidence. t1451 and t571 belong to ST398, a common MSSA clone in the local community. The epidemiology of spa types varied; e.g., incident cases of t279 was detected in 10 months, t1451 was detected in 6 months and t148 in 3 months. Among the 14 sets of twins and triplets with MSSA isolates, 12 (86%) shared the same spa type as their sibling(s). Of the 58 infants with >1 MSSA isolate, 12 (21%) acquired new spa-types. No spa type(s) predominated in the 19 episodes of invasive infections. In 6 infants with both colonizing and invasive isolates, colonizing and invasive isolates were the same spa type(s) in 5.
Conclusion. Spa typing demonstrated that MSSA isolates in our NICU exhibited substantial genetic heterogeneity. While these data do not elucidate acquisition route(s), they suggest infants are acquiring MSSA from multiple sources, likely including family members and the local community. Ongoing sequencing studies are examining common spa types to further understand transmission dynamics. Tetracyclines  Tigecycline   VISA  81  23  33  90  80  100  52  100  0  100  100  57  100  VRSA  87  43  51  94  87  94  64  100  6  92  97  71  100 
